Rare Disease Genetic Testing Market Size, Share, Growth Analysis, By Disease Type(Neurological Disease, Immunological Disorders), By Technology(Next-Generation Sequencing (NGS), Array Technology), By Specialty(Molecular Genetic Tests, Chromosomal Genetic Tests), By End-Use(Research Laboratories & CROs, Hospitals & Clinics), By Regional Scope(North America, Europe) - Industry Forecast 2024-2031

Rare Disease Genetic Testing Market Competitive Landscape

To understand the competitive landscape, we are analyzing key Rare Disease Genetic Testing Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Rare Disease Genetic Testing Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

• Quest Diagnostics Inc.
• Centogene N.V.
• Invitae Corp.
• 3billion, Inc.
• Arup Laboratories
• Eurofins Scientific
• Strand Life Sciences
• Ambry Genetics
• Perkin Elmer, Inc.
• Realm IDX, Inc.
• Macrogen, Inc.
• Baylor Genetics
• Color Genomics, Inc.
• Health Network Laboratories
• PreventionGenetics
• Progenity, Inc.
• Coopersurgical, Inc.
• Fulgent Genetics Inc.
• Myriad Genetics, Inc.
• Laboratory Corporation of America Holdings
• Opko Health, Inc.
• Artemis DNA